Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

492 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer.
Visani L, Livi L, Ratosa I, Orazem M, Ribnikar D, Saieva C, Becherini C, Salvestrini V, Scoccimarro E, Valzano M, Cerbai C, Desideri I, Bernini M, Orzalesi L, Nori J, Bianchi S, Morandi A, Meattini I. Visani L, et al. Among authors: morandi a. Radiother Oncol. 2022 Dec;177:40-45. doi: 10.1016/j.radonc.2022.10.023. Epub 2022 Oct 28. Radiother Oncol. 2022. PMID: 36349599
Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis.
Becherini C, Visani L, Caini S, Bhattacharya IS, Kirby AM, Nader Marta G, Morgan G, Salvestrini V, Coles CE, Cortes J, Curigliano G, de Azambuja E, Harbeck N, Isacke CM, Kaidar-Person O, Marangoni E, Offersen B, Rugo HS, Morandi A, Lambertini M, Poortmans P, Livi L, Meattini I. Becherini C, et al. Among authors: morandi a. Cancer Treat Rev. 2023 Sep;119:102586. doi: 10.1016/j.ctrv.2023.102586. Epub 2023 Jun 15. Cancer Treat Rev. 2023. PMID: 37336117 Free article. Review.
Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis.
Salvestrini V, Kim K, Caini S, Alkner S, Ekholm M, Skyttä T, Becherini C, Coles CE, Kaidar-Person O, Offersen B, de Azambuja E, Visani L, Cortes J, Harbeck N, Rugo HS, Isacke CM, Marangoni E, Morandi A, Lambertini M, Poortmans P, Livi L, Meattini I. Salvestrini V, et al. Among authors: morandi a. Radiother Oncol. 2023 Sep;186:109805. doi: 10.1016/j.radonc.2023.109805. Epub 2023 Jul 10. Radiother Oncol. 2023. PMID: 37437610 Free article. Review.
Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO).
Kaidar-Person O, Meattini I, Boersma LJ, Becherini C, Cortes J, Curigliano G, de Azambuja E, Harbeck N, Rugo HS, Del Mastro L, Gennari A, Isacke CM, Vestmø Maraldo M, Marangoni E, Nader Marta G, Mjaaland I, Salvestrini V, Spanic T, Visani L, Morandi A, Lambertini M, Livi L, Coles CE, Poortmans P, Offersen BV. Kaidar-Person O, et al. Among authors: morandi a. Radiother Oncol. 2024 Jun;195:110060. doi: 10.1016/j.radonc.2023.110060. Epub 2023 Dec 19. Radiother Oncol. 2024. PMID: 38122852 Free article. Review.
International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations.
Meattini I, Becherini C, Caini S, Coles CE, Cortes J, Curigliano G, de Azambuja E, Isacke CM, Harbeck N, Kaidar-Person O, Marangoni E, Offersen BV, Rugo HS, Salvestrini V, Visani L, Morandi A, Lambertini M, Poortmans P, Livi L; Consensus Panellist Group. Meattini I, et al. Among authors: morandi a. Lancet Oncol. 2024 Feb;25(2):e73-e83. doi: 10.1016/S1470-2045(23)00534-X. Lancet Oncol. 2024. PMID: 38301705 Review.
Acetyl-CoA carboxylase 1 controls a lipid droplet-peroxisome axis and is a vulnerability of endocrine-resistant ER+ breast cancer.
Bacci M, Lorito N, Smiriglia A, Subbiani A, Bonechi F, Comito G, Morriset L, El Botty R, Benelli M, López-Velazco JI, Caffarel MM, Urruticoechea A, Sflomos G, Malorni L, Corsini M, Ippolito L, Giannoni E, Meattini I, Matafora V, Havas K, Bachi A, Chiarugi P, Marangoni E, Morandi A. Bacci M, et al. Among authors: morandi a. Sci Transl Med. 2024 Feb 28;16(736):eadf9874. doi: 10.1126/scitranslmed.adf9874. Epub 2024 Feb 28. Sci Transl Med. 2024. PMID: 38416843
FADS1/2 control lipid metabolism and ferroptosis susceptibility in triple-negative breast cancer.
Lorito N, Subbiani A, Smiriglia A, Bacci M, Bonechi F, Tronci L, Romano E, Corrado A, Longo DL, Iozzo M, Ippolito L, Comito G, Giannoni E, Meattini I, Avgustinova A, Chiarugi P, Bachi A, Morandi A. Lorito N, et al. Among authors: morandi a. EMBO Mol Med. 2024 Jul;16(7):1533-1559. doi: 10.1038/s44321-024-00090-6. Epub 2024 Jun 26. EMBO Mol Med. 2024. PMID: 38926633 Free PMC article.
Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers.
El-Botty R, Morriset L, Montaudon E, Tariq Z, Schnitzler A, Bacci M, Lorito N, Sourd L, Huguet L, Dahmani A, Painsec P, Derrien H, Vacher S, Masliah-Planchon J, Raynal V, Baulande S, Larcher T, Vincent-Salomon A, Dutertre G, Cottu P, Gentric G, Mechta-Grigoriou F, Hutton S, Driouch K, Bièche I, Morandi A, Marangoni E. El-Botty R, et al. Among authors: morandi a. Nat Commun. 2023 Jul 14;14(1):4221. doi: 10.1038/s41467-023-40022-5. Nat Commun. 2023. PMID: 37452026 Free PMC article.
492 results